Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Although adjuvant chemotherapy with gemcitabine is standard care for resected pancreatic cancer, S-1 has shown non-inferiority to gemcitabine for advanced disease. We aimed to investigate the non-inferiority of S-1 to gemcitabine as adjuvant chemotherapy for pancreatic cancer in terms of overall sur...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 388; no. 10041; pp. 248 - 257
Main Authors:	Uesaka, Katsuhiko, Boku, Narikazu, Fukutomi, Akira, Okamura, Yukiyasu, Konishi, Masaru, Matsumoto, Ippei, Kaneoka, Yuji, Shimizu, Yasuhiro, Nakamori, Shoji, Sakamoto, Hirohiko, Morinaga, Soichiro, Kainuma, Osamu, Imai, Koji, Sata, Naohiro, Hishinuma, Shoichi, Ojima, Hitoshi, Yamaguchi, Ryuzo, Hirano, Satoshi, Sudo, Takeshi, Ohashi, Yasuo
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 16.07.2016 Elsevier Limited
Subjects:	Aged Antimetabolites, Antineoplastic - administration & dosage Cancer therapies Carcinoma, Ductal - mortality Carcinoma, Ductal - pathology Carcinoma, Ductal - therapy Chemotherapy Chemotherapy, Adjuvant Clinical trials Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug Combinations Female Humans Injections, Intravenous Internal Medicine Kaplan-Meier Estimate Lymphatic Metastasis Male Middle Aged Mortality Oxonic Acid - administration & dosage Pancreatectomy Pancreatic cancer Pancreatic Neoplasms - mortality Pancreatic Neoplasms - therapy Proportional Hazards Models Survival Tegafur - administration & dosage
ISSN:	0140-6736, 1474-547X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!